Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study-Reference-Cited by-同舟云学术

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study

Published:2017-01-08 Issue:4 Volume:35 Page:528-535
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Epperla Narendranath¹,Hamadani Mehdi¹,Cashen Amanda F.²,Ahn Kwang W.¹,Oak Eunhye²,Kanate Abraham S.³,Calzada Oscar⁴,Cohen Jonathon B.⁴,Farmer Luke⁵,Ghosh Nilanjan⁵,Tallarico Michael⁶,Nabhan Chadi⁶,Costa Luciano J.⁷,Kenkre Vaishalee P.⁸,Hari Parameswaran N.¹,Fenske Timothy S.¹

Affiliation:

1. Division of Hematology and Oncology; Medical College of Wisconsin; Milwaukee WI USA

2. Division of Medical Oncology; Washington University School of Medicine; St. Louis MO USA

3. Division of Hematology and Oncology; West Virginia University; Morgantown WV USA

4. Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta GA USA

5. Department of Hematology and Oncology; Levine Cancer Institute/Carolinas HealthCare System; Charlotte NC USA

6. Division of Hematology and Oncology; University of Chicago; Chicago IL USA

7. Bone Marrow Transplantation and Cell Therapy Program; University of Alabama; Birmingham AL USA

8. Division of Hematology and Oncology; University of Wisconsin; Madison WI USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference20 articles.

1. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group;Harris;Blood,1994

2. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades;Swerdlow;Hum Pathol,2002

3. Mantle cell lymphoma;Cortelazzo;Crit Rev Oncol Hematol,2012

4. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004;Zhou;Cancer,2008

5. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?;Chaudhary;Bone Marrow Transplant,2013

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis;Leukemia & Lymphoma;2024-07-08

2. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas;Frontiers in Oncology;2024-07-01

3. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review;Journal of Blood Medicine;2024-05

4. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

5. A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma;Blood Research;2023-12-31